Sham Mailankody

33PUBLICATIONS

155CO-AUTHORS

Molecular targetsPredictive and prognostic markersGene expression (incl. microarray and other genome-wide approaches)Haematological tumoursCancer genetics

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (33)

Sort by Publication Date:

|Jun 27, 2026

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

|Jun 17, 2026

CAR T cells take on precancers.

|Jun 12, 2026

Genomic features do not account for differences in multiple myeloma risk by ancestry.

|May 01, 2026

A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients.

|Apr 12, 2026

Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.

Hamza Hashmi, Tara Sebastian, Sridevi Rajeeve

|Mar 31, 2026

Pharmacokinetics of CAR T cells in multiple myeloma - the good, the bad, and the ugly.

Maximilian Merz, Eric Jurgens, David Fandrei

Pageof 6

Frequent Collaborators

22 joint publications

Urvi Shah

21 joint publications

Carlyn Tan

19 joint publications

Hani Hassoun

19 joint publications

Malin L Hultcrantz

18 joint publications

Saad Z Usmani

18 joint publications

Sergio Giralt

18 joint publications

Heather Landau

18 joint publications

Kylee Maclachlan

17 joint publications

Gunjan Shah

16 joint publications

Neha Korde

Frequent Collaborators

22 joint publications

Urvi Shah

21 joint publications

Carlyn Tan

19 joint publications

Hani Hassoun

19 joint publications

Malin L Hultcrantz